Position in NVCT
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$9,059
-$1,767 QoQ
Shares Held
1,172
-18.3% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Legal & General Group Plc holds $3,030,824,133 across 242 Biotechnology names. NVCT ranks #230 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,955,764 | $873,326,855 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
732,054 | $565,614,201 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
934,881 | $309,324,075 | |
| 4 | RPRX |
Royalty Pharma plc
|
3,362,872 | $161,316,968 | |
| 5 | INCY |
Incyte Corp
|
1,543,188 | $145,244,853 | |
| 6 | INSM |
INSMED Inc
|
787,079 | $128,703,157 | |
| 7 | ARGX |
Argenx SE
|
150,850 | $110,158,211 | |
| 8 | MRNA |
Moderna, Inc.
|
750,841 | $38,142,721 |
All Filings in NVCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,059 | 1,172 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $10,826 | 1,434 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $8,632 | 1,434 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $10,711 | 1,434 | Shares | Defined | 2025-08-12 | |
| 2024-03-31 | $6,896 | 841 | Shares | Defined | 2025-05-29 | |
| 2023-12-31 | $7,013 | 841 | Shares | Defined | 2025-05-29 | |
| 2023-09-30 | $10,840 | 841 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $13,430 | 841 | Shares | Defined | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||